4yr
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx - Annals of Surgical Oncology
Source : https://link.springer.com/article/10.1245/s10434-022-12225-5
Background The American Joint Committee on Cancer (AJCC) 8th edition pathologic prognostic staging (PPS) incorporates anatomic and biologic factors. The OncotypeDX Breast Recurrence Score (RS) was included based on the initial report of the TAILORx trial, with T1-2N0 hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer patients who had a RS 25 in 15.6% of the patients.
Conclusions: Patients with T1-2N0 HR HER2− breast cancer and a RS
-
Breast Cancer Connect4yrThanks, All, for your input! What do others think ... will this make the guidelines? Please explain.
-
Sarah Mougalian, Yale Cancer Center4yrInteresting analysis that tries to make the case for expanding ODx RS into staging guidelines. Stage is helpful for describing a cancer and is helpful conceptually, the ODx is what dictates treatment. Staging should correlate with prognosis (and therefore cancers that are staged II should have worse prognosis than stage I), which argues for expansion as per this study.
-
Albert Dekker4yrI would say it is useful but will never make to guidelines